 LEXINGTON, Mass., Jan. 05, 2022 GLOBE NEWSWIRE -- Agenus NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will participate in the following upcoming investor conferences: 